Akari Reports $19.3M Loss, Extends Cash Runway to December, Announces Whitehawk Collaboration
AKTX has more than doubled off its 52-week low of $3.015.
Summary
Akari Therapeutics reported a $19.3M H1 2026 net loss, extended cash runway to December 2026, and disclosed a new Whitehawk collaboration and a huge authorized share increase.
Key Events · Earnings and Guidance · AKTX
-
Net Loss Widens to $19.3M
Six-month net loss of $19.3 million, up from $5.6 million in H1 2025, driven by $12.1 million in non-cash impairment charges on goodwill and IPR&D.
-
Cash Runway Only to December 2026
Cash balance of $7.7 million as of June 30, 2026, funds operations only into December 2026; going concern warning reiterated.
-
Authorized Shares Soar to 4.37 Trillion
Shareholders approved an increase in authorized ordinary shares to 4,365,687,180,943, enabling massive future dilution.
-
Whitehawk Collaboration Announced
Subsequent event: strategic research collaboration with Whitehawk Therapeutics to evaluate PH1 payload technology in combination with Whitehawk's ADC platform.
Analysis · AKTX · Life Sciences
Akari Therapeutics' Q2 2026 10-Q reveals a $19.3 million net loss for the first half of 2026, driven by $12.1 million in non-cash impairment charges on goodwill and IPR&D. Cash of $7.7 million at June 30, 2026, extends the runway only to December 2026, and the company reiterates substantial doubt about its ability to continue as a going concern. The filing also discloses a strategic research collaboration with Whitehawk Therapeutics and a massive increase in authorized shares to over 4.3 trillion, setting the stage for further extreme dilution.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 52.8% of the 195 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.69%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTX was trading at $7.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $3.02 to $49.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.